Podcasts about novel approaches

Session 4 ‘Novel Approaches to Pathogen Detection and Sepsis Diagnostics' from the 5th World Sepsis Congress. Featuring Evdoxia Kyriazopoulou, Thorsten Brenner, Larissa May, Irit Gat-Viks, Olawale Ajose, and Konrad Reinhart as your moderator.

Thackeray's comic masterpiece, Vanity Fair, is a Victorian novel looking back to Regency England as an object both of satire and nostalgia. Thackeray's disdain for the Regency is present throughout the book, not least in the proliferation of hapless characters called George, yet he also draws heavily on his childhood experiences to unfold a complex story of fractured families, bad marriages and the tyranny of debt. In this episode, Colin Burrow and Rosemary Hill join Tom to discuss Thackeray's use of clothes, curry and the rapidly changing topography of London to construct a turbulent society full of peril and opportunity for his heroine, Becky Sharp, and consider why the Battle of Waterloo was such a recurrent preoccupation in literature of the period.Non-subscribers will only hear an extract from this episode. To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsnaRead more in the LRB:John Sutherland on Thackeray:https://www.lrb.co.uk/the-paper/v22/n02/john-sutherland/wife-overboardRosemary Hill on 'Frock Consciousness':https://www.lrb.co.uk/the-paper/v22/n02/rosemary-hill/frock-consciousness Hosted on Acast. See acast.com/privacy for more information.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning recaps two presentations delivered at the Society for Cardiothoracic Surgery in Great Britain and Ireland Annual Meeting 2025. Chapters 00:00 Intro 02:57 "Teamship," Sir Woodward 09:23 Virtual Surgery Training, Dr. Ahmed 12:55 Upcoming Lung Surgery Trials 14:48 Needle Aspiration & Forceps Biopsy 17:26 Approaches to Clinical Trial Designs 22:10 Noninvasive Ventilation Cardiac Impact 24:59 Lung Volume Reduction, Severe Emphysema 29:22 How To—Upper Ministernotomy 30:45 Valve-Sparing ARR Using Reimplant Tech 32:02 ARCA Management Exploration 33:59 Upcoming Events 34:41 WTS Webinar Series 35:32 Closing The first presentation was delivered by Sir Clive Woodward, the Rugby World Cup-winning coach, who gave an inspiring talk on "Teamship" and winning behaviors. The second presentation that Joel recaps was delivered by Professor Shafi Ahmed, a multiaward-winning surgeon and an evangelist for augmented and virtual reality, who discussed livestreaming operations, using virtual reality in surgical operations, and virtual medical school.   Joel also reviews recent JANS articles on the diagnostic yield and synergistic impact of needle aspiration and forceps biopsy with electromagnetic navigation bronchoscopy for peripheral pulmonary lesions, the challenges of conventional and novel approaches to clinical trial designs in cardiovascular medicine, the impact of noninvasive ventilation before and after cardiac surgery for preventing cardiac and pulmonary complications, and surgical and bronchoscopic lung volume reduction for severe emphysema.   In addition, Joel explores how to perform an upper ministernotomy, valve-sparing aortic root replacement using the reimplantation technique, and an exploration of anomalous right coronary artery management with Drs. Sameh Said and Vince Gaudiani. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Diagnostic Yield and Synergistic Impact of Needle Aspiration and Forceps Biopsy With Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions (CONFIDENT-ENB)  2.) Challenges of Conventional and Novel Approaches to Clinical Trial Designs in Cardiovascular Medicine  3.) Impact of Noninvasive Ventilation Before and After Cardiac Surgery for Preventing Cardiac and Pulmonary Complications   4.) Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-Analysis  CTSNET Content Mentioned  1.) How to Perform an Upper Ministernotomy  2.) Valve-Sparing Aortic Root Replacement Using the Reimplantation Technique  3.) Anomalous Right Coronary Artery Management: An Exploration With Sameh Said and Vince Gaudiani  Other Items Mentioned  1.) Webinar Series: Women in Cardiothoracic Surgery—Advancement Through Collaboration  2.) Career Center   3.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

When Wuthering Heights was published in December 1847, many readers didn't know what to make of it: one reviewer called it ‘a compound of vulgar depravity and unnatural horrors'. In this extended extract from episode three of ‘Novel Approaches', Patricia Lockwood and David Trotter join Thomas Jones to explore Emily Brontë's ‘completely amoral' novel. As well as questions of Heathcliff's mysterious origins and ‘obscene' wealth, of Cathy's ghost, bad weather, gnarled trees, even gnarlier characters and savage dogs, they discuss the book's intricate structure, Brontë's inventive use of language and the extraordinary hold that her story continues to exert over the imaginations of readers and non-readers alike.To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsna Hosted on Acast. See acast.com/privacy for more information.

When Wuthering Heights was published in December 1847, many readers didn't know what to make of it: one reviewer called it ‘a compound of vulgar depravity and unnatural horrors'. In this episode of ‘Novel Approaches', Patricia Lockwood and David Trotter join Thomas Jones to explore Emily Brontë's ‘completely amoral' novel. As well as questions of Heathcliff's mysterious origins and ‘obscene' wealth, of Cathy's ghost, bad weather, gnarled trees, even gnarlier characters and savage dogs, they discuss the book's intricate structure, Brontë's inventive use of language and the extraordinary hold that her story continues to exert over the imaginations of readers and non-readers alike.Non-subscribers will only hear an extract from this episode. To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsnaRead more in the LRB:David Trotter: Heathcliff Redoundinghttps://www.lrb.co.uk/the-paper/v46/n09/david-trotter/heathcliff-redoundingJohn Bayley: Kitchen Devilhttps://www.lrb.co.uk/the-paper/v12/n24/john-bayley/kitchen-devilAlice Spawls: If It Weren't for Charlottehttps://www.lrb.co.uk/the-paper/v39/n22/alice-spawls/if-it-weren-t-for-charlottePatricia Lockwood: What a Bear Wantshttps://www.lrb.co.uk/the-paper/v43/n16/patricia-lockwood/pull-off-my-headGet the books: https://lrb.me/crbooklist Hosted on Acast. See acast.com/privacy for more information.

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly... The post CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes appeared first on VJHemOnc.

Thomas Love Peacock didn't want to write novels, at least not in the form they had taken in the first half of the 19th century. In Crotchet Castle he rejects the expectation that novelists should reveal the interiority of their characters, instead favouring the testing of opinions and ideas. His ‘novel of talk', published in 1831, appears largely like a playscript in which disparate characters assemble for a house party next to the Thames before heading up the river to Wales. Their debates cover, among other things, the Captain Swing riots of 1830, the mass dissemination of knowledge, the emerging philosophy of utilitarianism and the relative merits of medieval and contemporary values. In this episode Clare is joined by Freya Johnston and Thomas Keymer to discuss where the book came from and its use of ‘sociable argument' to offer up-to-date commentary on the economic and political turmoil of its time.Non-subscribers will only hear an extract from this episode. To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsnaRead more in the LRB:Thomas Keymer on Peacockhttps://www.lrb.co.uk/the-paper/v40/n03/thomas-keymer/bring-some-madeiraPaul Foot: The not-so-great Reform Acthttps://www.lrb.co.uk/the-paper/v26/n09/paul-foot/shoy-hoys Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology... The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.

On one level, Mansfield Park is a fairytale transposed to the 19th century: Fanny Price is the archetypal poor relation who, through her virtuousness, wins a wealthy husband. But Jane Austen's 1814 novel is also a shrewd study of speculation, ‘improvement' and the transformative power of money.In this abridged version of the first episode of Novel Approaches, Colin Burrow joins Clare Bucknell and Thomas Jones to discuss Austen's acute reading of property and precarity, and why Fanny's moral cautiousness is a strategic approach to the riskiest speculation of all: marriage.To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsnaFind further reading and viewing on the episode page: https://lrb.me/mansfieldparkpod Hosted on Acast. See acast.com/privacy for more information.

This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.

On one level, Mansfield Park is a fairytale transposed to the 19th century: Fanny Price is the archetypal poor relation who, through her virtuousness, wins a wealthy husband. But Jane Austen's 1814 novel is also a shrewd study of speculation, ‘improvement' and the transformative power of money.In the first episode of Novel Approaches, Colin Burrow joins Clare Bucknell and Thomas Jones to discuss Austen's acute reading of property and precarity, and why Fanny's moral cautiousness is a strategic approach to the riskiest speculation of all: marriage.Non-subscribers will only hear an extract from this episode. To listen to the full episode, and all our other Close Readings series, subscribe:Directly in Apple Podcasts: https://lrb.me/applecrnaIn other podcast apps: https://lrb.me/closereadingsnaClare Bucknell is a fellow of All Souls College, Oxford, and hosted the Close Readings series On Satire with Colin Burrow. The Treasuries, her social history of poetry anthologies, was published in 2023.Thomas Jones is a senior editor at the LRB and host of the LRB Podcast. With Emily Wilson, he hosted the Close Readings series Among the Ancients.Next episode: ‘Crotchet Castle' by Thomas Love Peacock.Further reading from the LRB:John Mullan: Noticing and Not Noticinghttps://www.lrb.co.uk/the-paper/v36/n22/john-mullan/noticing-and-not-noticingColm Toíbìn: The Importance of Auntshttps://www.lrb.co.uk/the-paper/v33/n06/colm-toibin/the-importance-of-auntsW.J.T. Mitchell: In the Wildernesshttps://www.lrb.co.uk/the-paper/v15/n07/w.j.t.-mitchell/in-the-wilderness Hosted on Acast. See acast.com/privacy for more information.

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)... The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.

Clare Bucknell and Thomas Jones introduce their new Close Readings series, Novel Approaches. Joined by a variety of contemporary novelists and critics, they'll be exploring a dozen 19th-century British novels from Mansfield Park to New Grub Street, paying particular (though not exclusive) attention to the themes of money and property.The first episode will come out on Monday 27 January, on Austen's Mansfield Park.Clare Bucknell is a fellow of All Souls College, Oxford, and hosted the Close Readings series On Satire with Colin Burrow. The Treasuries, her social history of poetry anthologies, was published in 2023.Thomas Jones is a senior editor at the LRB and host of the LRB Podcast. With Emily Wilson, he hosted the Close Readings series Among the Ancients.The full list of texts for the series:Mansfield Park (1814) by Jane AustenCrotchet Castle (1831) by Thomas Love PeacockWuthering Heights (1847) by Emily BrontëVanity Fair (1847) by William Makepeace ThackerayNorth and South (1854) by Elizabeth GaskellAurora Leigh (1856) by Elizabeth Barrett BrowningAnthony Trollope (TBD)Mill on the Floss (1860) by George EliotOur Mutual Friend (1864) by Charles DickensWashington Square (1880)/Portrait of a Lady (1881) by Henry JamesKidnapped (1886) by Robert Louis StevensonThe Mayor of Casterbridge (1886) by Thomas HardyNew Grub Street (1891) by George Gissing Hosted on Acast. See acast.com/privacy for more information.

As our Close Readings series come to an end this year, you're probably wondering what's coming in 2025. We're delighted to announce there'll be four new series starting in January:‘Conversations in Philosophy' with Jonathan Rée and James WoodJonathan and James challenge a hundred years of academic convention by reuniting the worlds of philosophy and literature, as they consider how style, narrative, and the expression of ideas play through philosophical writers including Kierkegaard, Mill, Nietzsche, Woolf, Beauvoir and Camus.Reading list here:https://lrb.supportingcast.fm/posts/conversations-in-philosophy‘Fiction and the Fantastic' with Marina Warner, Anna Della Subin, Adam Thirlwell and Chloe Aridjis.Marina and guests will traverse the great parallel tradition of the literature of astonishment and wonder, dread and hope, from the 1001 Nights to Ursula K. Le Guin.Reading list here:https://lrb.supportingcast.fm/posts/fiction-and-the-fantastic‘Love and Death' with Seamus Perry and Mark FordMark and Seamus explore the oscillating power of outrage and grief, bitterness and consolation, in poetry in English from the Renaissance to the present day. Their series will consider the elegies of Milton, Hardy, Bishop, Plath and others at their most intimate and expressive.Reading list here:https://lrb.supportingcast.fm/posts/love-and-death‘Novel Approaches' with Clare Bucknell, Thomas Jones and other guestsClare, Tom and guests discuss a selection of 19th-century (mostly) English novels from Mansfield Park to New Grub Street, looking in particular at the roles played in the books by money and property.Reading list here:https://lrb.supportingcast.fm/posts/novel-approachesAnd the subscription will continue to include access to all our past Close Readings series.If you're not already a subscriber, sign up:Directly in Apple Podcasts: https://apple.co/3pJoFPqIn other podcast apps: https://lrb.me/closereadingsGIFTSIf you enjoy Close Readings, why not give it to another book lover in your life?Find our audio gifts here: https://lrb.supportingcast.fm/gifts Hosted on Acast. See acast.com/privacy for more information.

This week on the GeekWire Podcast, we sit down with some of the Seattle region’s “Uncommon Thinkers” — inventors, scientists, technologists and entrepreneurs transforming industries and driving positive change in the world. We recorded the episode on location, backstage at the GeekWire Gala, where we recognized five Uncommon Thinkers through this annual awards program, presented in partnership with Greater Seattle Partners. Speaking on the episode are: Uri Shumlak, co-founder and chief scientist at Zap Energy, a physicist leading a team in pursuit of fusion energy, taking a different approach from others in the field. Read the profile. Ingrid Swanson Pultz, CTO at Mopac Biologics, and translational advisor at the UW Institute for Protein Design, a microbiologist who led the development of a gluten-destroying enzyme. Read the profile. Chris Dunckley, director of chemistry and engineering of TerraPower Isotopes, a chemical engineer who leads a team turning radioactive waste into cancer therapy. Read the profile. Andy Lapsa, aerospace engineer and CEO of Stoke Space, a company focused on developing fully and rapidly reusable space vehicles using a liquid cooling technique for re-entry. Read the profile. Also featured in in the Uncommon Thinkers series: Hanna Hajishirzi of the Allen Institute for AI and the UW's Allen School of Computer Science & Engineering, who focuses on open-source Ai models. Read the profile. With GeekWire's Todd Bishop. Edited by Curt Milton.See omnystudio.com/listener for privacy information.

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage and Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Discussion of OpenNotes - Questions for Our Panel of Experts

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that... The post Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks appeared first on VJHemOnc.

Dr. John Sweetenham and Dr. Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple myeloma, and the 7-year analysis of the ECHELON-1 trial in classical Hodgkin lymphoma. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and the host of the ASCO Daily News Podcast. I'm delighted to be joined again this year by Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center in New York. We're going to be discussing some of the key abstracts in hematologic malignancies that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod.  Marc, it's great to have you back on the podcast. Dr. Marc Braunstein: It's a pleasure to be back, John.  Dr. John Sweetenham: There are some exciting abstracts to be presented at this year's meeting, and I would like to begin, if we can, with Abstract 6501. As you know, this reports the four-year results from the OPTIC trial of ponatinib in patients with chronic-phase CML and the T315I mutation. Can you tell us about the trial and about these latest follow-up results? Dr. Marc Braunstein: Sure. Well, we've made tremendous progress in managing patients with CML in the past two decades using these oral tyrosine kinase inhibitors such as ponatinib. Ponatinib is a third-generation TKI that has activity in both Philadelphia-positive ALL as well as CML, and can overcome the resistance mutation you mentioned, called the T315I mutation, which is sometimes found following prior TKI therapy. The OPTIC study is a multicenter phase 2 randomized study of various doses of ponatinib in 283 chronic phase CML patients who had received 2 or more prior lines of therapy or those who had the presence of a T315I mutation, with the current analysis examining the major remission at 48 months, PFS, as well as OS. Of note, in this study, after patients have achieved a major remission with a transcript level of 1% or less, the study allowed for dose reduction of ponatinib from the original dose of either 45 milligrams or 30 milligrams to a reduced dose of 15 milligrams.  So, when we look at the results, we find that the patients who had the highest overall response rates and higher rates of molecular remission were those who received the 45-milligram dose. And remember, these patients were allowed to be dose-reduced to the 15-milligram dose once they achieved a molecular remission of 1% or less. In addition, the rates of overall survival were highest in the 45-milligram dose as well. When looking at the T315I subgroup, the rates of molecular remission, the depth of remission, and the rates of progression-free survival, in general, were lower in that subgroup, but still higher in the 45-milligram dose than the 35- milligram dose.  Furthermore, when looking at the rates of treatment-emergent adverse events leading to discontinuation, they were 8% in the 45-milligram dose compared to 14% in the 30-milligram dose and 5% in the patients who only received the 15-milligram dose. The authors have concluded that the 45-milligram dose, with the potential to be reduced to 15 milligrams after achieving 1% or less of the BCR-ABL transcript level, seems to be the right balance between efficacy and safety.  Dr. John Sweetenham: Thanks, Marc. In the longer term, do you think that this study will, in any way, affect the position of ponatinib in the treatment algorithm for CML? Is it going to remain as a second or third-line option, or do you think there's any chance it will be moved up? Dr. Marc Braunstein: Well, that's a great question. There are other TKIs, such as asciminib, that also target the T315I mutation, and that mutation tends to develop after prior first-line or second-line TKI therapy. But given its activity in both ALL and CML, I think it's certainly reasonable to expect that ponatinib will be used in earlier lines of therapy given its efficacy in later lines. Dr. John Sweetenham: Let's change gears and move the focus to acute myeloid leukemia. There has been a lot of discussion around frailty in many different malignancies, but the impact of frailty on outcomes in AML is maybe something that hasn't been quite so well studied. In Abstract 6506, investigators did a population-based study in Ontario, Canada, that assessed the patient's frailty risk and the impact that might have on outcomes. What are your takeaways from this study, and how do you think these data will help optimize treatment decisions?  Dr. Marc Braunstein: Yeah, I'm glad we're talking about this abstract John, because frailty scores are increasingly being used in hematologic malignancies to help guide goals and intensity of care. And as opposed to using age or performance status alone, these composite frailty assessment tools, such as the MFI tool that they used in this particular study, take into account multiple variables that are both physiologic, such as the patient's comorbidities, as well as social, and what kind of support system do they have, and things of that nature. And that accounts for their overall fitness. So, in this retrospective cohort study that was a population-based study in Ontario between 2006 and 2021, they looked at 5,450 patients retrospectively with acute leukemia and grouped those patients into 3 categories based on this frailty index. Patients who are either fit, somewhere in the middle between fit or frail, which they call pre-frail, or frail. And they looked at outcomes such as overall survival, comparing patients who got intensive chemotherapy regimens for induction or those who got non-intensive therapy for induction. Patients in either group could have been assigned to either fit, pre-frail, or frail although there are much more fit patients than those who got intensive induction.  And so, looking at their findings, it was noted that patients who were in the frail category, not entirely unexpectedly, had lower overall survival when compared to those who were fit or pre-frail. I think the value of a study like this is not just to highlight the benefit of frailty scores to help predict which patients may ultimately have a shorter survival, but also to help potentially guide which patients may be more suitable for intensive versus less intensive induction. I will note that this study was conducted in an era where we didn't have the same sorts of less intensive induction that are very effective in less fit patients, such as the combination of azacytidine and venetoclax, which is commonly used in less fit patients nowadays. So, the study may encompass patients who didn't have access to that therapy because it wasn't available during that time. But I think it still, overall, does highlight the fact that assessing fitness or frailty in acute myeloid leukemia is important for predictive value. Dr. John Sweetenham: I agree. Marc, I don't know what your thoughts are on this, but it goes either way. I mean, I think that, if I remember the numbers correctly, 25% of fit patients received non-intensive therapy. So, is there a missed opportunity there for that group of patients who actually may have tolerated the intensive therapy but it was never offered? Dr. Marc Braunstein: That's an excellent point, John, and I think that highlights the importance of frailty indices because they take into account much more than one particular factor, or even just a subjective assessment of the patient in real time when they're first presenting. And they may have disease-specific features that are decreasing, say one element of their assessment such as their performance status. So, really taking these composite fitness scores into account may actually allow you to escalate therapy in a patient who may actually be fit but maybe perceived as less fit when they present. Dr. John Sweetenham: Yeah. So, I think, as you mentioned, there are better treatment options out there now maybe than there were at the time this study was conducted. Nevertheless, there may still be that opportunity for more intensive therapy for some of these patients when they are more holistically assessed.  Let's move on and switch gears once again and talk about a study in multiple myeloma, the so-called IMROZ study, which is Abstract 7500. So, this is a study looking at treatment options for transplant-ineligible patients with newly diagnosed multiple myeloma. Some of these patients may not have a chance for subsequent therapy if they are not eligible for transplant. What are your thoughts on this study? Do you think we're closer to a new standard of care for patients who are not going to proceed to an autologous stem cell transplant?  Dr. Marc Braunstein: It seems like every year there's a new standard of care for newly diagnosed multiple myeloma because there's so much data emerging, which is just wonderful. So, I think as background, at the 2023 ASH meeting, the IsKia study was presented, which is a randomized phase 3 study in newly diagnosed transplant-eligible patients. And that was using isatuximab with carfilzomib, lenalidomide, and dexamethasone upfront and that study did show a benefit in terms of reducing minimal residual disease compared to carfilzomib, lenalidomide, and dexamethasone alone. But that study was looking at fit newly diagnosed patients who were going on to stem cell transplant. Right now, the standard of care for patients who are not eligible for transplant is generally to use a 2 or 3-drug regimen, such as daratumumab, lenalidomide, and dexamethasone, based on the phase 3 MAYA study. But this study is really unique in that it looks at using a quadruplet regimen in patients who are transplant ineligible or not intended to go for transplant.  So, the phase 3 IMROZ study was a randomized study of 446 patients that compared isatuximab, bortezomib, lenalidomide, and dexamethasone to bortezomib, lenalidomide, and dexamethasone alone. So, a quad versus a triplet regimen. The primary endpoint in this study was progression-free survival, but they also looked at secondary endpoints, such as complete response rate and minimal residual disease negativity.   Just to quickly highlight the results and then discuss the standard of care, the median duration of treatment in this study was 53 months in the quad regimen and 31 months in the control arm. At a median follow-up of about 60 months, the progression-free survival was not reached with the quad regimen versus 54 months in the triplet, and that was a significant difference. In addition, the safety profile was pretty much consistent with the class, there were a bit more grade three or higher treatment-emergent adverse events with the ESA-containing regimen, 92% versus 84%, but no difference in adverse events leading to discontinuation in either arm.   So, this study is certainly compelling in terms of using quadruplet-based regimens that contain an anti-CD38 monoclonal antibody for newly diagnosed patients who are not intended to undergo transplant. I think at the meeting, I will be interested to see the patient population that was included. Patients who are over the age of 80, for example, are excluded. So, I would like to know more about their fitness level and performance status. But I think it's clear, John, that using quad regimens over triplet regimens is just consistently superior in terms of efficacy outcomes. Dr. John Sweetenham: Right. I guess that, even though maybe we can't focus on the specific agents right now, it looks as if quad regimens are going to be the standard of care regimens for the future in this group. Do you think that is fair?  Dr. Marc Braunstein: Very likely. Dr. John Sweetenham: Absolutely. Well, that's a pretty challenging group of patients.   And so to move on again, let's talk about another, perhaps equally challenging group - patients with mantle cell lymphoma, particularly those who carry certain mutations. The so-called SYMPATICO study, which is reported in Abstract 7007, presents data on the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who carry a TP53 mutation. We know that this mutation confers a high risk of early progressive disease and poorer outcomes when these patients are treated with standard chemoimmunotherapy for mantle cell. Trials to date have been limited to small single-arm studies. Can you tell us a little bit about this study and the outcomes and what you think it means for the future?  Dr. Marc Braunstein: As a background, although BTK inhibitors such as ibrutinib have yet to be approved for newly diagnosed mantle cell lymphoma, acalabrutinib and zanubrutinib, which are second-generation BTK inhibitors, are FDA-approved for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market. The lead author of this abstract, Dr. Michael Wang, had presented a late-breaking data from the phase 3 SYMPATICO trial at ASH last year, in which 267 patients with relapsed or refractory mantle cell lymphoma after one to five prior lines of therapy were randomized to receive the combination of ibrutinib plus the BCL-2 inhibitor venetoclax or ibrutinib plus placebo. That study showed there was a 32 versus 22-month progression-free survival with a hazard ratio of 0.65 at a median follow-up of 51 months, indicating the PFS benefit of the combination of ibrutinib and venetoclax compared to ibrutinib with placebo.   So that leads us to this subgroup analysis in the current study being presented at ASCO, in which they looked at a subgroup of patients with mantle cell lymphoma who are at very high risk for treatment failure and early relapse - those are patients who have a mutation in TP53, which again is high risk for treatment failure. This abstract examined an open-label cohort of 44 first-line patients, as well as 75 patients who were in the relapse/refractory cohort, and compared to patients who either did or did not have the P53 mutation. When we look at the progression-free survival outcomes, the median progression-free survival in the first-line cohort of patients who did not have a P53 mutation was not reached, whereas those with the P53 mutation had a median progression-free survival of 22 months, which is still meaningful but still less than those who did not have a P53 mutation. Which again is not entirely unexpected. But the overall response rate of the combination of ibrutinib and venetoclax was very high at 90%, and the median duration of response was about 21 months.  Now comparing this to the relapse/refractory cohort, in those without a P53 mutation, the progression-free survival of the combination of ibrutinib and venetoclax was about 47 months versus those who don't have the P53 mutation was about 21 months with an overall response rate of 80%. I think one takeaway looking at this comparison of the first-line and relapse/refractory setting is that patients seem to do very similar in terms of overall response rate and progression-free survival, whether they were in the first line or in the later lines of treatment if they had the P53 mutation, which says that the combination of ibrutinib and venetoclax is effective no matter which phase of the disease the patient might be in, indicating its overall activity and being strong.    Dr. John Sweetenham: Yeah, I thought that was an interesting observation, actually, how similar the outcomes were in those two groups.  Dr. Marc Braunstein: No, I agree. And I think although patients with TP53 mutations did comparatively worse than those without the mutation according to progression-free survival, overall response rate, or complete remission rates, they did seem to be similar whether a patient was in first-line or relapsed refractory if they were P53 mutant and were treated with this combination. So, I think we need further data in the first line, such as the data that's awaiting publication from the TRIANGLE study, which is examining upfront ibrutinib. But certainly, BTK inhibitors have significant activity in either the first line or the relapse setting of mantle cell lymphoma.  Dr. John Sweetenham: Great. Thanks, Marc.  Let's wind up with one more abstract, and this is Abstract 7053. It's a 7-year analysis of the so-called ECHELON-1 study. This was a study comparing the standard of care, ABVD, with the same regimen with bleomycin substituted by brentuximab vedotin for patients with previously untreated advanced-stage classical Hodgkin lymphoma. The study at the time it was originally reported, resulted in a significant practice change in the first-line therapy of Hodgkin's lymphoma. We now have mature follow-up. What are your take-homes from this study? Dr. Marc Braunstein: The ECHELON-1 study has certainly been a practice-changing clinical trial where, as you said, brentuximab with the backbone of AVD was compared to ABVD, which was the prior standard. And this was examined in newly diagnosed patients with classical Hodgkin lymphoma who were at advanced-stage, stage 3 or 4. The publication, first of the progression-free survival, and more recently, in the New England Journal of Medicine in 2022, where we saw the 6-year overall survival was 94% with the brentuximab-containing arm versus 89% in the control arm, established the brentuximab AVD, or otherwise called AAVD, as the standard of care in advanced stage newly diagnosed classical Hodgkin lymphoma. The current study is now reporting 7-year follow-up on about 1,300 randomized patients who were enrolled in this impressive study.   Though at a median follow-up of 89 months now, the 7-year overall survival was quite similar, 94% versus 89%, again favoring the brentuximab-containing arm. In particular, this was driven by patients who had stage 4 disease or those patients who were aged less than 60 in subgroup analyses. So, what I take away from this abstract in the 7-year follow-up of the ECHELON-1 is that brentuximab with AVD remains the standard of care for previously untreated advanced-stage classical Hodgkin lymphoma. It is worth noting that the SWOG S1826 study that was presented at ASCO last year compared nivolumab with AVD compared to brentuximab AVD and did show a slight PFS advantage of 94% versus 86% with nivolumab AVD. Obviously, these were different studies with different patient populations enrolled, so we're really just cross-comparing different studies. But I think brentuximab AVD, given the survival benefit that is retained now at seven years in the current abstract, still remains the standard of care for advanced-stage classical Hodgkin lymphoma. The role of immune checkpoint inhibitors like nivolumab is making headway in terms of treating newly diagnosed patients as well. Dr. John Sweetenham: Yeah, thanks, Marc. I mean, one of the observations that I thought was of interest in this study was the outcome for patients who were PET-2 positive, when you compare AAVD and ABVD. It does seem as if even in those patients who are PET-2 positive, having had AAVD, they still apparently have a better outcome than those who received ABVD in that situation who were PET-2 positive. So, I think that's another interesting observation. I'm not quite sure what it means, except speaking to the overall superior efficacy of that regimen. Dr. Marc Braunstein: You make a great point, John, because it's worth noting that in ECHELON-1, a PET scan was done after cycle 2, but the study was not PET-adapted. So even if you had a positive PET, you continued for the full six cycles of treatment. But PET-2 status is often used in various studies of Hodgkin lymphoma to guide whether to give additional cycles or escalate therapy. So, I think the benefit of presenting those subgroups is that even if you were PET-2 positive, you still did better by continuing on the brentuximab-containing regimen. Dr. John Sweetenham: Yeah, exactly. I mean, the other important takeaway message, I think, is that the outcome for patients with advanced Hodgkin lymphoma seems to continue to steadily improve, which is great news and also really remarkable. And I'm excited to see there may be some additional data presented at one of the late-breaking abstracts in this year's meeting, so it will truly be interesting to see what that shows us as well.  Dr. Marc Braunstein: Incredible. Dr. John Sweetenham: Well, Marc, as always, thank you for sharing your insights with us today on the ASCO Daily News Podcast. We look forward very much to hearing the updated data from these abstracts at the meeting.  Dr. Marc Braunstein: As do I and thank you so much for inviting me again.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest: Dr. Marc Braunstein @docbraunstein   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness   Dr. Marc Braunstein: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen Oncology Research Funding (Institution): Janssen, Celgene/BMS

In this Better Edge podcast episode, Edward M. Schaeffer, MD, PhD, chair and the Edmund Andrews Professor of Urology at Northwestern Medicine, discusses the PREVENT Randomized Trial (PReclude infection EVEnts with No prophylaxis Transperineal), a study in which he was co-primary investigator. The trial, funded by the National Cancer Institute, compared the outcomes of transperineal biopsy without antibiotic prophylaxis to transrectal biopsy with targeted prophylaxis.

- Why Chemotherapy Causes Treatment Side Effects & Discomfort - Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomatitis, Diarrhea, Constipation, Weight Gain or Weight Loss - How Health Care Teams Approach Management & Prevention of These Common GI Side Effects - Prevention Strategies - The Role of the Oncology Nurse in Preventing Side Effects - Current Research Directions to Improve Control of GI Treatment Side Effects - Developing a Detailed Plan with Your Oncology Team to Manage & Prevent GI Chemotherapy Treatment Side Effects - The Importance of Being Prepared Before Treatment Starts - New Agents - The Importance of Clinical Trials - Communicating with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UBN865. CME credit will be available until January 29, 2025.Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerVallerie V. McLaughlin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aerami Therapeutics Holdings, Inc.; Aerovate Therapeutics, Inc.; Caremark LLC; CorVista Health, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; United Therapeutics Corporation; and Vertex Pharmaceuticals Incorporated.Grant/Research Support from Aerovate Therapeutics, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; SoniVie.Co-Chair/PlannerIoana R. Preston, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aerovate Therapeutics, Inc.; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.Grant/Research Support from Bellerophon Therapeutics; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UBN865. CME credit will be available until January 29, 2025.Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerVallerie V. McLaughlin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aerami Therapeutics Holdings, Inc.; Aerovate Therapeutics, Inc.; Caremark LLC; CorVista Health, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; United Therapeutics Corporation; and Vertex Pharmaceuticals Incorporated.Grant/Research Support from Aerovate Therapeutics, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; SoniVie.Co-Chair/PlannerIoana R. Preston, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aerovate Therapeutics, Inc.; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.Grant/Research Support from Bellerophon Therapeutics; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005

Dr. Ryan Potts is VP of Research and Head of the Induced Proximity Platform at Amgen that works on ways to bring two or more molecules in close proximity to each other to tackle drug targets that are currently considered “undruggable.” Ryan conducts early-stage research to discover new high-impact medicines for serious diseases that have a high unmet medical need. Their work examines biological pathways, drug targets, disease drivers, and new ways to create drugs that have the desired effects. He also leads Amgen's Research & Development Postdoctoral Fellows Program. Outside of science, Ryan enjoys spending quality time with his family and his kids. They enjoy exploring the natural world, hiking, and exploring the nearby Santa Monica Mountains and local beaches. Ryan is also an avid traveler and sports fan. Ryan received his BS in biology from the University of North Carolina at Chapel Hill, and he was awarded his PhD in cellular and molecular biology from UT Southwestern Medical Center. After completing his PhD, Ryan served on the faculty at UT Southwestern Medical Center for eight years before accepting a position on the faculty at St. Jude Children's Research Hospital. He joined the team at Amgen in 2020. In this interview, he shares more about his life and science.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer CME Available: auau.auanet.org/node/39487 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the indications for germline testing in prostate cancer patients. 2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer. 3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas and Pfizer, Inc AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.